Autoimmune pancerebellitis associated with pembrolizumab therapy
- 10 July 2018
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 91 (2), 91-93
- https://doi.org/10.1212/wnl.0000000000005781
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) AntibodiesJAMA Neurology, 2017
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureAnnals Of Oncology, 2016
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic CancerJAMA Neurology, 2016
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals Of Oncology, 2015
- Infections of the CerebellumNeurologic Clinics, 2014
- Disorders of the Cerebellum: Ataxia, Dysmetria of Thought, and the Cerebellar Cognitive Affective SyndromeThe Journal of Neuropsychiatry and Clinical Neurosciences, 2004
- Disorders of the Cerebellum: Ataxia, Dysmetria of Thought, and the Cerebellar Cognitive Affective SyndromeThe Journal of Neuropsychiatry and Clinical Neurosciences, 2004